[Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases]

Sauvain, M J; Schalm, S B; Bérthet, G; Bolz, D; Cannizzaro, E; Hofer, M; Kaiser, D; Saurenmann, R K; Bolt, I B (2010). [Swiss registry for TNF-alpha blockers in children and adolescents with rheumatological diseases]. Praxis - schweizerische Rundschau für Medizin, 99(11), pp. 649-54. Bern: Huber

Full text not available from this repository.

We created a registry to evaluate long term outcome, efficacy and adverse events for children treated wit TNF-alpha inhibitors in Switzerland. 106 patients (68 female/38 male) were included. 61 patients were treated with Etanercept (Enbrel) and 45 with Infliximab (Remicade). Concomitant treatment at baseline included corticosteroids in 26% and Methotrexate in 75% of the patients. Subjective disease activity three months after initiation of TNF-alpha was better in 81%, worse in 4% and stable in 15% of the patients. In total 24 adverse events in 21 patients were reported. Treatment with TNF-alpha inhibitors seems to be safe and effective for children and adolescents with rheumatologic diseases.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine 04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology 04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology > Centre of Competence for Psychosomatic Medicine
UniBE Contributor:	Sauvain, Marie-Josèphe, Schalm, Susanne, Hofer Marti, Michael, Bolt, Isabel Bettina
ISSN:	1661-8157
Publisher:	Huber
Language:	German
Submitter:	Anette van Dorland
Date Deposited:	04 Oct 2013 14:07
Last Modified:	05 Dec 2022 14:00
PubMed ID:	20506089
URI:	https://boris.unibe.ch/id/eprint/152 (FactScience: 196572)